236 related articles for article (PubMed ID: 32327714)
21. Preubiquitinated chimeric ErbB2 is constitutively endocytosed and subsequently degraded in lysosomes.
Vuong TT; Berger C; Bertelsen V; Rødland MS; Stang E; Madshus IH
Exp Cell Res; 2013 Feb; 319(3):32-45. PubMed ID: 23127513
[TBL] [Abstract][Full Text] [Related]
22. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathways: targeting hsp90--who benefits and who does not.
Scaltriti M; Dawood S; Cortes J
Clin Cancer Res; 2012 Sep; 18(17):4508-13. PubMed ID: 22718860
[TBL] [Abstract][Full Text] [Related]
24. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
[TBL] [Abstract][Full Text] [Related]
25. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
26. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
27. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
[TBL] [Abstract][Full Text] [Related]
28. E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells.
Samant RS; Clarke PA; Workman P
Proc Natl Acad Sci U S A; 2014 May; 111(18):6834-9. PubMed ID: 24760825
[TBL] [Abstract][Full Text] [Related]
29. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells.
Yallowitz A; Ghaleb A; Garcia L; Alexandrova EM; Marchenko N
Cell Death Dis; 2018 May; 9(6):621. PubMed ID: 29799521
[TBL] [Abstract][Full Text] [Related]
30. Regulation of Ubiquitin-like with Plant Homeodomain and RING Finger Domain 1 (UHRF1) Protein Stability by Heat Shock Protein 90 Chaperone Machinery.
Ding G; Chen P; Zhang H; Huang X; Zang Y; Li J; Li J; Wong J
J Biol Chem; 2016 Sep; 291(38):20125-35. PubMed ID: 27489107
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
32. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
33. Identification of new biomarkers for clinical trials of Hsp90 inhibitors.
Zhang H; Chung D; Yang YC; Neely L; Tsurumoto S; Fan J; Zhang L; Biamonte M; Brekken J; Lundgren K; Burrows F
Mol Cancer Ther; 2006 May; 5(5):1256-64. PubMed ID: 16731758
[TBL] [Abstract][Full Text] [Related]
34. Proteasomal deubiquitylase activity enhances cell surface recycling of the epidermal growth factor receptor in non-small cell lung cancer.
Wang S; Wang T; Yang Q; Cheng S; Liu F; Yang G; Wang F; Wang R; Yang D; Zhou M; Duan C; Zhang Y; Liu H; Dai Z; Tian K; Liu S
Cell Oncol (Dordr); 2022 Oct; 45(5):951-965. PubMed ID: 36129611
[TBL] [Abstract][Full Text] [Related]
35. ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.
Li D; Marchenko ND
Oncotarget; 2017 Jan; 8(4):5823-5833. PubMed ID: 27791982
[TBL] [Abstract][Full Text] [Related]
36. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
37. A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair.
Bruns AF; Yuldasheva N; Latham AM; Bao L; Pellet-Many C; Frankel P; Stephen SL; Howell GJ; Wheatcroft SB; Kearney MT; Zachary IC; Ponnambalam S
PLoS One; 2012; 7(11):e48539. PubMed ID: 23139789
[TBL] [Abstract][Full Text] [Related]
38. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
39. Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way.
Lerdrup M; Hommelgaard AM; Grandal M; van Deurs B
J Cell Sci; 2006 Jan; 119(Pt 1):85-95. PubMed ID: 16352662
[TBL] [Abstract][Full Text] [Related]
40. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
